{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:02:06Z","timestamp":1795089726905,"version":"4.10.2"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Postgraduate Scientific Research Innovation Project of Hunan Province","award":["CX20210974"],"award-info":[{"award-number":["CX20210974"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"crossref","award":["2020JJ5513"],"award-info":[{"award-number":["2020JJ5513"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific research Fund of hunan provincial education department","award":["19A418"],"award-info":[{"award-number":["19A418"]}]},{"name":"Scientific Research\u00a0Fund\u00a0Project\u00a0of\u00a0Hunan\u00a0Provinci al Health\u00a0Commission","award":["20201973"],"award-info":[{"award-number":["20201973"]}]},{"name":"Central government funds for guiding local scientific and Technological Development","award":["2021QZY016"],"award-info":[{"award-number":["2021QZY016"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823"],"award-info":[{"award-number":["2020SK51823"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by chronic hyperglycemia causing from insufficient insulin signaling because of insulin resistance or defective insulin secretion, and may induce severe complications and premature death. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are oral drugs used to reduce hyperglycemia in patients with T2DM, including empagliflozin, ertugliflozin, dapagliflozin and canagliflozin. The primary objective of this article is to examine the clinical benefit, safety, and tolerability of the four SGLT2\u00a0inhibitors approved by the US FDA. SGLT2 inhibitors increase urinary glucose excretion via inhibiting SGLT2 to decrease renal reabsorption of filtered glucose and reduce the renal threshold for glucose. Rather than stimulating insulin release, SGLT2 inhibitors improve \u03b2-cell function by improving glucotoxicity, as well as\u00a0reduce insulin resistance and increase insulin sensitivity. Early clinical trials have confirmed the beneficial effects of SGLT2 in T2DM with acceptable safety and excellent tolerability. In recent years, SGLT2 inhibitors has been successively approved by the FDA to decrease cardiovascular death and decrease the risk of stroke and cardiac attack in T2DM adults who have been diagnosed with cardiovascular disease, treating heart failure (HF) with reduced ejection fraction and HF with\u00a0preserved ejection fraction, and treat diabetic kidney disease (DKD), decrease the risk of hospitalization for HF in T2DM and DKD patients. SGLT2 inhibitors are expected to be an effective treatment for T2DM patients with non alcoholic fatty liver disease. SGLT2 inhibitors have a similar safety profile to placebo or other active control groups, with major adverse events such as Ketoacidosis or hypotension and genital or urinary tract infections.<\/jats:p>","DOI":"10.1186\/s12933-022-01512-w","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T12:03:58Z","timestamp":1653480238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":176,"title":["The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management"],"prefix":"10.1186","volume":"21","author":[{"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"issue":"2","key":"1512_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142243","volume":"131","author":"SI Taylor","year":"2021","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021;131(2): e142243.","journal-title":"J Clin Invest"},{"issue":"9548","key":"1512_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","volume":"368","author":"KH Yoon","year":"2006","unstructured":"Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1512_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","volume":"9","author":"N Marx","year":"2021","unstructured":"Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9(1):46\u201352.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1512_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","journal-title":"Nat Med"},{"issue":"2","key":"1512_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dom.14251","volume":"23","author":"CM Khoo","year":"2021","unstructured":"Khoo CM, Deerochanawong C, Chan SP, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations. Diabetes Obes Metab. 2021;23(2):299\u2013317.","journal-title":"Diabetes Obes Metab"},{"issue":"1S","key":"1512_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.amjcard.2017.05.009","volume":"120","author":"J Thrasher","year":"2017","unstructured":"Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Cardiol. 2017;120(1S):S4\u201316.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1512_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):17.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1512_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14.","journal-title":"Diseases"},{"key":"1512_CR9","volume-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. Sodium-glucose cotransporter-2 (SGLT2) inhibitors. Silver Spring: U.S. Food and Drug Administration; 2016."},{"key":"1512_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100007","volume":"1","author":"Z Bloomgarden","year":"2020","unstructured":"Bloomgarden Z, Handelsman Y. Management and prevention of cardiovascular disease for type 2 diabetes: integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am J Prev Cardiol. 2020;1: 100007.","journal-title":"Am J Prev Cardiol"},{"issue":"15","key":"1512_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"1512_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173(4):278\u201386.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1512_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"1512_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.numecd.2021.02.006","volume":"31","author":"Y Bai","year":"2021","unstructured":"Bai Y, Jin J, Zhou W, Zhang S, Xu J. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(5):1365\u201374.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1512_CR15","volume-title":"JardianceTM press releases","author":"Jardiance","year":"2014","unstructured":"Jardiance. JardianceTM press releases. Boehringer Ingelheim; 2014."},{"key":"1512_CR16","volume-title":"InvokanaTM press releases","author":"LLC","year":"2020","unstructured":"LLC. InvokanaTM press releases. Raritan: Janssen Research & Development; 2020."},{"key":"1512_CR17","volume-title":"SteglatroTM press releases","author":"Steglatro","year":"2017","unstructured":"Steglatro. SteglatroTM press releases. Darmstadt: Merck; 2017."},{"key":"1512_CR18","volume-title":"FarxigaTM press releases","author":"Farxiga","year":"2021","unstructured":"Farxiga. FarxigaTM press releases. Cambridge: AstraZeneca; 2021."},{"key":"1512_CR19","volume-title":"JardianceTM prescribing information","author":"Jardiance","year":"2014","unstructured":"Jardiance. JardianceTM prescribing information. Indianapolis: Eli Lilly; 2014."},{"issue":"5","key":"1512_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/dom.12064","volume":"15","author":"LH Chen","year":"2013","unstructured":"Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(5):392\u2013402.","journal-title":"Diabetes Obes Metab"},{"key":"1512_CR21","volume-title":"SteglatroTM prescribing information","author":"Steglatro","year":"2017","unstructured":"Steglatro. SteglatroTM prescribing information. Darmstadt: Merck; 2017."},{"issue":"10","key":"1512_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346.","journal-title":"Drugs"},{"issue":"9","key":"1512_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-013-0064-9","volume":"73","author":"S Elkinson","year":"2013","unstructured":"Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013;73(9):979\u201388.","journal-title":"Drugs"},{"issue":"4","key":"1512_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A. Ertugliflozin: first global approval. Drugs. 2018;78(4):513\u20139.","journal-title":"Drugs"},{"issue":"15","key":"1512_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40265-014-0298-1","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(15):1769\u201384.","journal-title":"Drugs"},{"issue":"18","key":"1512_CR26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191\u2013209.","journal-title":"Drugs"},{"key":"1512_CR27","volume-title":"InvokanaTM prescribing information","author":"LLC","year":"2020","unstructured":"LLC. InvokanaTM prescribing information. Raritan: Janssen Research & Development; 2020."},{"key":"1512_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8: 777861.","journal-title":"Front Med"},{"key":"1512_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga T, Kikuchi O, Kobayashi M, et al. SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1\u201312.","journal-title":"Mol Metab"},{"key":"1512_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"WT Garvey","year":"2018","unstructured":"Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32\u20137.","journal-title":"Metabolism"},{"issue":"3","key":"1512_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/dia.2013.0167","volume":"16","author":"S Mudaliar","year":"2014","unstructured":"Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137\u201344.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"1512_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2174\/1871529X18666180206120444","volume":"18","author":"D Milonas","year":"2018","unstructured":"Milonas D, Tziomalos K. Sodium-glucose cotransporter 2 inhibitors and ischemic stroke. Cardiovasc Hematol Disord Drug Targets. 2018;18(2):134\u20138.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"5","key":"1512_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/pds.4985","volume":"29","author":"D Li","year":"2020","unstructured":"Li D, Wu T, Wang T, et al. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiol Drug Saf. 2020;29(5):582\u201390.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1512_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262\u201374.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1512_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499\u2013508.","journal-title":"J Clin Invest"},{"key":"1512_CR36","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1136","author":"S Kullmann","year":"2021","unstructured":"Kullmann S, Hummel J, Wagner R, et al. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care. 2021. https:\/\/doi.org\/10.2337\/dc21-1136.","journal-title":"Diabetes Care"},{"issue":"1","key":"1512_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1512_CR38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"1512_CR39","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3390\/ijms21061907","volume":"21","author":"Y Sumida","year":"2020","unstructured":"Sumida Y, Yoneda M, Tokushige K, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(6):1907.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1512_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7570\/jomes.2019.28.1.18","volume":"28","author":"CH Jung","year":"2019","unstructured":"Jung CH, Mok JO. The effects of hypoglycemic agents on non-alcoholic fatty liver disease: focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J Obes Metab Syndr. 2019;28(1):18\u201329.","journal-title":"J Obes Metab Syndr"},{"key":"1512_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.609135","volume":"11","author":"C Wong","year":"2021","unstructured":"Wong C, Yaow CYL, Ng CH, et al. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis. Front Endocrinol. 2021;11: 609135.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1512_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","volume":"11","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites. 2020;11(1):22.","journal-title":"Metabolites"},{"issue":"7","key":"1512_CR43","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/jdi.13457","volume":"12","author":"KY Cho","year":"2021","unstructured":"Cho KY, Nakamura A, Omori K, et al. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2021;12(7):1272\u20137.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"1512_CR44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"1512_CR45","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/jdi.13289","volume":"11","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Shimabukuro M, Machii N, et al. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: multi-center placebo-controlled double-blind randomized trial. J Diabetes Investig. 2020;11(6):1551\u201363.","journal-title":"J Diabetes Investig"},{"issue":"7","key":"1512_CR46","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/dom.14377","volume":"23","author":"H Ghanim","year":"2021","unstructured":"Ghanim H, Batra M, Green K, et al. Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. Diabetes Obes Metab. 2021;23(7):1614\u201323.","journal-title":"Diabetes Obes Metab"},{"key":"1512_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154936","volume":"127","author":"R Marfella","year":"2021","unstructured":"Marfella R, D\u2019Onofrio N, Trotta MC, et al. Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2021;127: 154936.","journal-title":"Metabolism"},{"issue":"21","key":"1512_CR48","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"6","key":"1512_CR49","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","volume":"14","author":"T Mason","year":"2021","unstructured":"Mason T, Coelho-Filho OR, Verma S, et al. Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc Imaging. 2021;14(6):1164\u201373.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1512_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323\u201334.","journal-title":"Circulation"},{"issue":"1","key":"1512_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0977-z","volume":"19","author":"A Fuchigami","year":"2020","unstructured":"Fuchigami A, Shigiyama F, Kitazawa T, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1512_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356\u201363.","journal-title":"Diabetes Care"},{"issue":"3","key":"1512_CR53","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/dom.14261","volume":"23","author":"SJ Han","year":"2021","unstructured":"Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab. 2021;23(3):682\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"1512_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3342","volume":"370","author":"KB Filion","year":"2020","unstructured":"Filion KB, Lix LM, Yu OH, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020;370: m3342.","journal-title":"BMJ"},{"key":"1512_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573.","journal-title":"BMJ"},{"issue":"2","key":"1512_CR56","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.pcd.2020.08.017","volume":"15","author":"XB Wei","year":"2021","unstructured":"Wei XB, Wei W, Ding LL, Liu SY. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. Prim Care Diabetes. 2021;15(2):208\u201311.","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"1512_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1512_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1512_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495\u2013502.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1512_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","volume":"4","author":"JH Wu","year":"2016","unstructured":"Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"1512_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"6","key":"1512_CR62","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"6","key":"1512_CR63","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/dom.14352","volume":"23","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial. Diabetes Obes Metab. 2021;23(6):1426\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"1512_CR64","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","volume":"76","author":"JL Januzzi Jr","year":"2020","unstructured":"Januzzi JL Jr, Xu J, Li J, et al. Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction. J Am Coll Cardiol. 2020;76(18):2076\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1512_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-020-01209-y","volume":"20","author":"YW Yu","year":"2021","unstructured":"Yu YW, Zhao XM, Wang YH, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20(1):25.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1512_CR66","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117(2):495\u2013507.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1512_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"15","key":"1512_CR68","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"22","key":"1512_CR69","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"24","key":"1512_CR70","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"14","key":"1512_CR71","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368.","journal-title":"JAMA"},{"issue":"5","key":"1512_CR72","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program. Circulation. 2018;138(5):458\u201368.","journal-title":"Circulation"},{"issue":"4","key":"1512_CR73","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejhf.2083","volume":"23","author":"P Dewan","year":"2021","unstructured":"Dewan P, Docherty KF, Bengtsson O, et al. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail. 2021;23(4):632\u201343.","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"1512_CR74","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142(23):2205\u201315.","journal-title":"Circulation"},{"issue":"15","key":"1512_CR75","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580\u201391.","journal-title":"JAMA"},{"issue":"11","key":"1512_CR76","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20(11):2585\u201397.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1512_CR77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","volume":"21","author":"D Giugliano","year":"2022","unstructured":"Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21(1):42.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1512_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"1512_CR79","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"1","key":"1512_CR80","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/dom.14211","volume":"23","author":"V Okunrintemi","year":"2021","unstructured":"Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab. 2021;23(1):276\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1512_CR81","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52(5):1545\u201356.","journal-title":"Stroke"},{"issue":"1","key":"1512_CR82","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","volume":"77","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77(1):94\u2013109.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1512_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","volume":"35","author":"A Piperidou","year":"2021","unstructured":"Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021;35(1):12\u201325.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"1512_CR84","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","volume":"99","author":"M Oshima","year":"2021","unstructured":"Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021;99(4):999\u20131009.","journal-title":"Kidney Int"},{"issue":"9","key":"1512_CR85","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1512_CR86","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"1512_CR87","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"5","key":"1512_CR88","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/ehf2.13509","volume":"8","author":"K Mozawa","year":"2021","unstructured":"Mozawa K, Kubota Y, Hoshika Y, et al. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Heart Fail. 2021;8(5):4161\u201373.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"1512_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1512_CR90","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1512_CR91","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s00125-016-4017-1","volume":"59","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sj\u00f6str\u00f6m CD. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59(9):2036\u20139.","journal-title":"Diabetologia"},{"issue":"1","key":"1512_CR92","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJ Heerspink","year":"2017","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1512_CR93","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1512_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1512_CR95","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/dom.14286","volume":"23","author":"GA Silverii","year":"2021","unstructured":"Silverii GA, Monami M, Mannucci E. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2021;23(4):1052\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1512_CR96","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","volume":"8","author":"M Oshima","year":"2020","unstructured":"Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020;8(11):903\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1512_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13717","author":"M Murashima","year":"2021","unstructured":"Murashima M, Tanaka T, Kasugai T, et al. Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice. J Diabetes Investig. 2021. https:\/\/doi.org\/10.1111\/jdi.13717.","journal-title":"J Diabetes Investig"},{"key":"1512_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02943-2","author":"M Kanbay","year":"2021","unstructured":"Kanbay M, Tapoi L, Ureche C, et al. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. Int Urol Nephrol. 2021. https:\/\/doi.org\/10.1007\/s11255-021-02943-2.","journal-title":"Int Urol Nephrol"},{"issue":"9896","key":"1512_CR99","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941\u201350.","journal-title":"Lancet"},{"issue":"12","key":"1512_CR100","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392.","journal-title":"Diabetologia"},{"issue":"2","key":"1512_CR101","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","volume":"41","author":"B Bode","year":"2013","unstructured":"Bode B, Stenl\u00f6f K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41(2):72\u201384.","journal-title":"Hosp Pract"},{"issue":"3","key":"1512_CR102","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13879","volume":"22","author":"KY Cho","year":"2020","unstructured":"Cho KY, Nomoto H, Nakamura A, et al. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: an open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). Diabetes Obes Metab. 2020;22(3):458\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1512_CR103","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"1","key":"1512_CR104","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018 executive summary. Endocr Pract. 2018;24(1):91\u2013120.","journal-title":"Endocr Pract"},{"issue":"2","key":"1512_CR105","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2013a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11.","journal-title":"Am Heart J"},{"issue":"3","key":"1512_CR106","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.dsx.2019.04.035","volume":"13","author":"G Chawla","year":"2019","unstructured":"Chawla G, Chaudhary KK. A complete review of empagliflozin: most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(3):2001\u20138.","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"1512_CR107","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/1573399812666160613113556","volume":"13","author":"MJ Levine","year":"2017","unstructured":"Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13(4):405\u201323.","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"1512_CR108","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1512_CR109","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"1512_CR110","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36(12):4015\u201321.","journal-title":"Diabetes Care"},{"issue":"4","key":"1512_CR111","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12325-015-0198-0","volume":"32","author":"T Kadowaki","year":"2015","unstructured":"Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015;32(4):306\u201318.","journal-title":"Adv Ther"},{"key":"1512_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12933-014-0169-9","volume":"14","author":"R Nishimura","year":"2015","unstructured":"Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1512_CR113","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138.","journal-title":"Diabetes Care"},{"issue":"9","key":"1512_CR114","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstr\u00e5le","year":"2014","unstructured":"Ridderstr\u00e5le M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691\u2013700.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1512_CR115","first-page":"188","volume":"33","author":"M Babar","year":"2021","unstructured":"Babar M, Hussain M, Ahmad M, Akhtar L. Comparison Of efficacy and safety profile of empagliflozin as a combination therapy in obese type 2 diabetic patients. J Ayub Med Coll Abbottabad. 2021;33(2):188\u201391.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"6","key":"1512_CR116","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019;48(6):859\u201366.","journal-title":"Age Ageing"},{"issue":"16","key":"1512_CR117","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"1512_CR118","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","volume":"9","author":"J Jensen","year":"2021","unstructured":"Jensen J, Omar M, Kistorp C, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021;9(2):106\u201316.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1512_CR119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.","journal-title":"BMC Med"},{"issue":"3","key":"1512_CR120","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"SA Jabbour","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740\u201350.","journal-title":"Diabetes Care"},{"issue":"12","key":"1512_CR121","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004\u201316.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"1512_CR122","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"1512_CR123","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/dom.13681","volume":"21","author":"L Ji","year":"2019","unstructured":"Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1512_CR124","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/dom.13251","volume":"20","author":"R Aronson","year":"2018","unstructured":"Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1512_CR125","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13116","volume":"20","author":"S Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1512_CR126","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21(4):1027\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1512_CR127","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1512_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002484","volume":"9","author":"S Dagogo-Jack","year":"2021","unstructured":"Dagogo-Jack S, Pratley RE, Cherney DZI, et al. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021;9(1): e002484.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"1512_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577","volume":"9","author":"JR Donnan","year":"2019","unstructured":"Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1): e022577.","journal-title":"BMJ Open"},{"issue":"11","key":"1512_CR130","doi-asserted-by":"publisher","first-page":"dgaa586","DOI":"10.1210\/clinem\/dgaa586","volume":"105","author":"FH Shi","year":"2020","unstructured":"Shi FH, Li H, Yue J, et al. Clinical adverse events of high-dose vs. low-dose sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of 51 randomized clinical trials. J Clin Endocrinol Metab. 2020;105(11):dgaa586.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1512_CR131","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/pds.4943","volume":"29","author":"H Tang","year":"2020","unstructured":"Tang H, Yang K, Li X, Song Y, Han J. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2020;29(2):161\u201372.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1512_CR132","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jdi.12966","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T. Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors. J Diabetes Investig. 2019;10(2):193\u20135.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1512_CR133","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/jdi.13137","volume":"11","author":"M Yasuda","year":"2020","unstructured":"Yasuda M, Iizuka K, Kato T, et al. Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report. J Diabetes Investig. 2020;11(3):745\u20137.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1512_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.145","volume":"3","author":"R Pelletier","year":"2020","unstructured":"Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble JM. The association of sodium-glucose cotransporter 2 inhibitors with cancer: an overview of quantitative systematic reviews. Endocrinol Diabetes Metab. 2020;3(3): e00145.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"10","key":"1512_CR135","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","volume":"60","author":"H Tang","year":"2017","unstructured":"Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862\u201372.","journal-title":"Diabetologia"},{"issue":"12","key":"1512_CR136","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1007\/s00125-017-4430-0","volume":"60","author":"S Kohler","year":"2017","unstructured":"Kohler S, Lee J, George JT, Inzucchi SE, Zinman B. Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia. 2017;60(12):2534\u20135.","journal-title":"Diabetologia"},{"key":"1512_CR137","volume-title":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Silver Spring: U.S. Food and Drug Administration; 2016."},{"issue":"1","key":"1512_CR138","doi-asserted-by":"publisher","first-page":"10293","DOI":"10.1038\/s41598-021-89752-w","volume":"11","author":"F Ata","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021;11(1):10293.","journal-title":"Sci Rep"},{"issue":"7","key":"1512_CR139","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS Lin","year":"2021","unstructured":"Lin DS, Lee JK, Chen WJ. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab. 2021;106(7):2133\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1512_CR140","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(9):1619\u201327.","journal-title":"Diabetes Obes Metab"},{"key":"1512_CR141","volume-title":"FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Silver Spring: U.S. Food and Drug Administration; 2016."},{"issue":"10","key":"1512_CR142","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","volume":"62","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Jardine M, Perkovic V, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019;62(10):1854\u201367.","journal-title":"Diabetologia"},{"issue":"5","key":"1512_CR143","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","volume":"45","author":"L Cheng","year":"2019","unstructured":"Cheng L, Li YY, Hu W, et al. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab. 2019;45(5):436\u201345.","journal-title":"Diabetes Metab"},{"key":"1512_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2903","author":"D Ruanpeng","year":"2017","unstructured":"Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2017. https:\/\/doi.org\/10.1002\/dmrr.2903.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"1512_CR145","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","volume":"18","author":"HL Tang","year":"2016","unstructured":"Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199\u2013206.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1512_CR146","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M18-0567","volume":"170","author":"M Fralick","year":"2019","unstructured":"Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture risk after initiation of use of canagliflozin: a cohort study. Ann Intern Med. 2019;170(3):155\u201363.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1512_CR147","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","volume":"44","author":"D Li","year":"2018","unstructured":"Li D, Yang JY, Wang T, Shen S, Tang H. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab. 2018;44(5):410\u20134.","journal-title":"Diabetes Metab"},{"key":"1512_CR148","doi-asserted-by":"publisher","DOI":"10.1159\/000520903","author":"RM See","year":"2021","unstructured":"See RM, Teo YN, Teo YH, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2021. https:\/\/doi.org\/10.1159\/000520903.","journal-title":"Pharmacology"},{"key":"1512_CR149","volume-title":"FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Silver Spring: U.S. Food and Drug Administration; 2016."},{"key":"1512_CR150","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2147\/DMSO.S300494","volume":"14","author":"L Shen","year":"2021","unstructured":"Shen L, Yang H, Fang X, et al. A clinical study on the association of sodium-glucose cotransporter 2 inhibitors and acute kidney injury among diabetic chinese population. Diabetes Metab Syndr Obes. 2021;14:1621\u201330.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1512_CR151","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","volume":"16","author":"M Zhao","year":"2020","unstructured":"Zhao M, Sun S, Huang Z, Wang T, Tang H. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol. 2020;16(1):70\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1512_CR152","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024655","volume":"100","author":"B Yu","year":"2021","unstructured":"Yu B, Dong C, Hu Z, Liu B. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a protocol for systematic review and meta-analysis. Medicine. 2021;100(8): e24655.","journal-title":"Medicine"},{"issue":"1","key":"1512_CR153","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jdi.13630","volume":"13","author":"T Horii","year":"2022","unstructured":"Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: a nationwide cohort study. J Diabetes Investig. 2022;13(1):42\u20136.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1512_CR154","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","volume":"41","author":"A Szalat","year":"2018","unstructured":"Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 inhibitors cause acute renal failure? plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018;41(3):239\u201352.","journal-title":"Drug Saf"},{"issue":"7","key":"1512_CR155","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2217\/pgs.13.61","volume":"14","author":"A T\u00f6njes","year":"2013","unstructured":"T\u00f6njes A, Kovacs P. SGLT2: a potential target for the pharmacogenetics of type 2 diabetes? Pharmacogenomics. 2013;14(7):825\u201333.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"1512_CR156","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","volume":"64","author":"W Rathmann","year":"2021","unstructured":"Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. Diabetologia. 2021;64(6):1201\u201312.","journal-title":"Diabetologia"},{"issue":"1","key":"1512_CR157","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/cpt.2153","volume":"110","author":"JL Katzmann","year":"2021","unstructured":"Katzmann JL, Mason AM, M\u00e4rz W, et al. Genetic variation in sodium-glucose cotransporter 2 and heart failure. Clin Pharmacol Ther. 2021;110(1):149\u201358.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1512_CR158","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/pgs.11.69","volume":"12","author":"U Enigk","year":"2011","unstructured":"Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119\u201326.","journal-title":"Pharmacogenomics"},{"issue":"8","key":"1512_CR159","doi-asserted-by":"publisher","first-page":"BSR20190299","DOI":"10.1042\/BSR20190299","volume":"39","author":"H Drexel","year":"2019","unstructured":"Drexel H, Leiherer A, Saely CH, et al. Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. Biosci Rep. 2019;39(8):BSR20190299.","journal-title":"Biosci Rep"},{"issue":"4","key":"1512_CR160","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/FPC.0000000000000268","volume":"27","author":"H Zimdahl","year":"2017","unstructured":"Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genom. 2017;27(4):135\u201342.","journal-title":"Pharmacogenet Genom"},{"issue":"4","key":"1512_CR161","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s13300-018-0449-6","volume":"9","author":"MJ Pereira","year":"2018","unstructured":"Pereira MJ, Lundkvist P, Kamble PG, et al. A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss. Diabetes Ther. 2018;9(4):1511\u201332.","journal-title":"Diabetes Ther"},{"issue":"9","key":"1512_CR162","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/jcph.506","volume":"55","author":"S Francke","year":"2015","unstructured":"Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061\u201372.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1512_CR163","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","volume":"55","author":"E Hoeben","year":"2016","unstructured":"Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A. Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2016;55(2):209\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1512_CR164","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/jcph.1866","volume":"61","author":"JC Marshall","year":"2021","unstructured":"Marshall JC, Liang Y, Sahasrabudhe V, et al. Meta-analysis of noncompartmental pharmacokinetic parameters of ertugliflozin to evaluate dose proportionality and UGT1A9 polymorphism effect on exposure. J Clin Pharmacol. 2021;61(9):1220\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"18","key":"1512_CR165","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1074\/jbc.RA118.002333","volume":"293","author":"MA Mitsche","year":"2018","unstructured":"Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain\u2013containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018;293(18):6958\u201368.","journal-title":"J Biol Chem"},{"issue":"9","key":"1512_CR166","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923\u201334.","journal-title":"Diabetologia"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01512-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01512-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01512-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T14:05:17Z","timestamp":1653487517000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01512-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01512-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}